Allergology

w230 - nAmb a 1 (Ambrosia elatior)

Test details

This test is useful when a ragweed pollen allergy is suspected and to identify the specific molecule that has previously caused a positive result in the associated allergen extract test.


Amb a 1 is a pectate lyase protein found in ragweed pollen.
The average prevalence of this molecule can exceed 90% in patients sensitised to ragweed pollen.
Cross-reactivity is possible with other pollens such as mugwort and sunflower.
Symptoms associated with an allergy to this molecule mainly include allergic rhinitis, conjunctivitis, and coughing caused an itchy throat; in some cases, the allergy may also cause skin symptoms and lead to bronchial asthma.
The assessment of sensitisations to Amb a 1 is considered important for selecting patients eligible for allergen-specific immunotherapy (AIT).

Sample type

Serum

Method

ChLIA

Preparation

Fasting for at least 8-12 hours before sampling

Storage conditions

Refer to the Health Service Charter to check storage conditions

Shipping

+2/+8°C

References

Hamilton RG. Allergic sensitization is a key risk factor for but not synonymous with allergic disease. J Allergy Clin Immunol. 2014 Aug;134(2):360-1. doi: 10.1016/j.jaci.2014.02.022. Epub 2014 Mar 31. PMID: 24698318.

Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, et al. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250. doi: 10.1111/pai.12563. PMID: 27288833.

analisi anticorpi anti recettore dell'acetilcolina (AChR) - Laboratorio Euroimmun
analisi anticorpi anti recettore

laboratory analysis

Find other tests

Total tau

This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.

Phosphorylated Tau (pTau181)

This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.

Anti–NMDAR Antibodies

Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.

Discover what’s new

Subscribe to the newsletter

Subscribe to our newsletter to be always updated.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.